BioSpace News Archive

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its drug Silmitasertib,

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that data presented from the HIV Prevention Trials Network (HPTN) 0

US Food & Drug Administration (FDA) clears Servo-air® mechanical ventilator for use with adult and pediatric patients dependent on intensive care ventilation expanding upon the Servo family of products available in the United States for decades. “FDA 510(k) clearance for Servo-air will broaden our US offering with a turbi

OmniPathology, an independent, physician-owned and operated pathology lab, and Total Testing Solutions (TTS), providers of health testing and consultations to business, today announced that they will partner to help companies test more employees using the Omni COVID-19 PCR test, which recently received FDA Emergency Use Authorization (EUA).

bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced that Stephen Squinto, Ph.D., has been named Vice Chairman of the Company’s Board of Directors, and David Elzi, Ph.D., has been appointed Vice President of Research in recognition of Dr. Elzi’s pivotal role in the Company’s scientific discoveries related to cancer therapeutics.

Proven Pharmaceuticals, LLC, a service provider to the healthcare and life-science industries, announced today that it is the exclusive authorized U.S. distributor of the Clungene® SARS-CoV-2 Virus (COVID-19) IgG/IgM Rapid Test Cassette.

Exeltis USA, Inc., a division of Insud Pharma, today communicated that 2 new articles published in Contraception and The European Journal of Contraception & Reproductive Health Care, reviewed the US Phase III clinical study involving Slynd™ (drospirenone) tablets 4 mg

Plakous Therapeutics, Inc. received a notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant providing up to $1,725,000 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health (NIH). The grant will assist Plakous’ developme

Byondis B.V. today announced that Quantum Leap Healthcare Collaborative™ (Quantum Leap) selected the company’s investigational antibody-drug conjugate (ADC) SYD985 ([vic-]trastuzumab duocarmazine) for a new investigational treatment arm in its ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.

Synaptive Medical, a leader in robotic surgical visualization, today announced the appointment of Marc R. Buntaine as chief executive officer.